Related Experiment Video
Updated: Aug 21, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
Published on: April 16, 2019
Non-alcoholic steatohepatitis
1Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands. pljansen@amc.uva.nl
Abstract:
Non-alcoholic steatohepatitis (NASH) is an underdiagnosed liver disease characterized by steatosis, necroinflammation and fibrosis. This disease may eventually develop into cirrhosis and hepatocellular carcinoma. NASH is highly prevalent among obese individuals and among patients with diabetes mellitus type 2. Non-alcoholic fatty liver (NAFL), a precursor of NASH, is the main cause of elevated serum liver enzymes among the general population. In NASH the liver is programmed to lipogenesis rather than to glycogenesis and herein insulin-resistance plays a major role. Gradual weight loss, physical exercise and drugs that improve insulin sensitivity are potential therapies.
Related Concept Videos
Cirrhosis I: Introduction
Hepatitis
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis II: Pathophysiology
Chronic Pancreatitis II: Pathophysiology
Viral Hepatitis I: Introduction

